Customize CRRSP14 Antibody

Description

Table 1: Antibody Nomenclature Examples from Literature

Antibody Designation	Target Protein	Clone/Isotype
CR9114	Influenza HA	IgG1
RVC20	Rabies G	Human mAb
N133/21	RGS14	IgG2a

RGS14 Antibody (N133/21)

Target: Regulator of G-protein signaling 14 (RGS14)
Function: Inhibits G protein α-subunit signaling; implicated in schizophrenia and Alzheimer’s disease .

CR9114: Broad-Spectrum Influenza Antibody

Target: Conserved stem region of influenza hemagglutinin (HA)
Function: Neutralizes influenza A (H1N1, H3N2, H5N1) and B subtypes via Fc-mediated effector functions .

Table 3: Neutralization and Protection Data (CR9114)

Viral Strain	Neutralization (IC₅₀)	In Vivo Protection	Mechanism
H1N1 (A/California/4/2009)	<0.1 µg/mL	Full (murine model)	HA stem binding
H3N2 (A/Hong Kong/1/1968)	<0.1 µg/mL	Full	FcγRIII activation
H2 (A/Ann Arbor/6/1960)	No neutralization	Partial	ADCC/ADCP

Key Findings:

Binds a hydrophobic groove in HA, inducing H-bonds via HCDR2 and HCDR3 loops .
Combines neutralization (A1/A2 subtypes) with Fc-mediated clearance (B/H2 subtypes) .

RVC20/RVC58: Rabies Virus Antibodies

Targets: Rabies virus glycoprotein (G)
Functions: Neutralize viral entry and induce ADCC/ADCP .

Table 4: Functional Comparison (RVC20 vs. RVC58)

Parameter	RVC20	RVC58
Binding Site	Pre-fusion G conformation	Arg333 salt bridge interaction
Neutralization	High (IC₅₀ <0.1 µg/mL)	Moderate (IC₅₀ ~1 µg/mL)
ADCC	Strong (Fold Induction >10)	Moderate (Fold Induction ~5)
Role	Prevents viral fusion	Blocks attachment to p75NTR

Key Findings:

RVC58’s Arg333 interaction disrupts neuroinvasiveness .
Cocktail (RVC20+RVC58) reduces cell-to-cell spread in vitro .

Critical Challenges in Antibody Research

Specificity and Cross-Reactivity:
- ~70% of commercial antibodies lack validation, leading to off-target effects .
- Example: RGS14 antibody (N133/21) validated against RGS12 to ensure specificity .
Breadth of Protection:
- CR9114’s pan-influenza activity stems from conserved HA epitopes, but universal vaccines remain elusive .
- RVC20/RVC58 highlight the need for cocktail therapies to counter viral evolution .

Product Specs

Buffer

**Preservative:** 0.03% Proclin 300
**Constituents:** 50% Glycerol, 0.01M PBS, pH 7.4

Form

Liquid

Lead Time

Made-to-order (14-16 weeks)

Synonyms

CRRSP14 antibody; At3g29050 antibody; MRI12.3 antibody; Putative cysteine-rich repeat secretory protein 14 antibody

Target Names

CRRSP14

Uniprot No.

Q9LJW1

Target Background

Database Links

KEGG: ath:AT3G29050

Protein Families

Cysteine-rich repeat secretory protein family

Subcellular Location

Secreted.

Q&A

Comprehensive Research Guide: Methodological Frameworks for Antibody Characterization in Academic Contexts
Recent advancements in antibody research have highlighted critical methodological considerations for academic investigators, particularly in validation protocols , structural epitope mapping , and cross-reactivity assessments . This guide synthesizes key research frameworks applicable to antibody studies, drawing parallels to hypothetical investigations of novel antibodies like CRRSP14.

Resolving Structural Epitope Mapping Discrepancies

Case Study: CR9114 antibody’s dual mechanism against influenza A/B stem epitopes .
Methodological Framework:

Cryo-EM Density Analysis: Resolve epitope-paratope interfaces at ≤4Å resolution .
Energetic Profiling: Calculate binding ΔG values using molecular dynamics simulations (e.g., FoldX or Rosetta) .
Epitope Conservation Scoring: Apply Shannon entropy metrics to identify immutable residues:
$H = -\sum_{i=1}^{20} p_i \ln p_i$
Where $p_i$ = amino acid frequency at position i across viral variants .

Advanced Consideration: For CRRSP14, compare cryo-EM epitope maps with X-ray crystallography data to resolve conformational flexibility artifacts .

Analyzing Neutralization Efficacy Across Viral Variants

Data Conflict Resolution: When in vitro neutralization (e.g., microneutralization IC50) contradicts in vivo protection (e.g., murine challenge ED50):

Mechanistic Profiling:
- Surface plasmon resonance (SPR) for kinetic binding analysis (ka/kd)
- High-content imaging of viral egress inhibition
Variant Impact Prediction: Use computational models weighting:
- Epitope residue mutation frequency
- Structural disruption (ΔΔG ≥1.5 kcal/mol = high risk)

Table 2: Variant Resistance Prediction Matrix

Mutation	Epitope Position	ΔΔG (kcal/mol)	Clinical Prevalence
E484K	RBD-12	+2.3	41%
N501Y	RBD-08	+1.1	67%

Advanced Epitope Conservation Strategies

Lessons from Influenza B Antibodies:

Head vs. Stem Targeting: CR8071 (head) shows lineage-specific neutralization vs. CR9114 (stem) with pan-viral efficacy .
Glycan Avoidance Engineering: Modify paratope residues to circumvent HA1-Asn38/332 glycans through:
- Site-saturation mutagenesis of CDR-H2
- In silico glycosylation modeling (GlyConnect DB)

CRRSP14 Adaptation: If targeting variable regions, employ ancestral sequence reconstruction to identify conserved structural motifs.

Standardizing Functional Characterization Protocols

Reproducibility Framework:

Neutralization Assays:
- Tier 1: Pseudovirus entry assays (IC50 ± SEM)
- Tier 2: Authentic virus plaque reduction (PRNT90)
- Tier 3: In vivo challenge models (minimum 3 species)
Reporting Standards:
- Normalize data to WHO reference sera
- Disclose passage history of viral stocks

Ethical Guidelines for Antibody Patenting

CR9114 Disclosure Model :

Deposit sequences in GenBank (Accession: JX213635-JX213640)
File provisional patents pre-publication
Implement material transfer agreements (MTAs) for academic access

Quick Inquiry

Personal Email Detected

Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *

Name*

Email*

Phone

Country

Source

Quantity&Size*

Product Name

Message

CRRSP14 Antibody